Endovascular Treatment for Worsening Stroke Caused by a Blocked Vertebrobasilar Artery
Tests a procedure to reopen the blocked artery against medicine alone in adults.
Plain-language title generated from the registry record
Registry title: Randomized Clinical Trial of Endovascular Treatment for Progressive Stroke With Vertebrobasilar Artery Occlusion
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose stroke from a blocked artery at the back of the brain got worse 24 hours to 14 days after it began.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Acute ischemic stroke with a blocked basilar artery, or a blocked dominant vertebral artery with the other vertebral artery blocked or underdeveloped. The first NIHSS score was below 10. The stroke then got worse to an NIHSS score of 10 or more, up 4 or more points, 24 hours to 14 days after it began. Randomization must happen within 24 hours of the worsening.
- Earlier treatment
- No earlier endovascular treatment for this stroke.
Main reasons for not taking part
- Bleeding in the brain on the first brain scan
- Worsening caused by brain bleeding, brain swelling or another clear cause
- Known pregnancy or breastfeeding
- Blood pressure above 185 mmHg systolic or 110 mmHg diastolic despite medication
- Life expectancy under 1 year
Read by machine on 9 November 2026.
Where in China
- Beijing Tiantan Hospital,Capital Medical UniversityBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Feng Gao
- Trial code
- NCT07557485
- Record updated
- 29 April 2026
- Original description
This multicenter, prospective, open-label randomized controlled trial with blinded assessment was designed to assess the efficacy and safety of endovascular treatment for progressive stroke due to vertebrobasilar artery occlusion.Read full original descriptionShow less
Safety and Efficacy of Endovascular Treatment for Progressive Stroke Due to Vertebrobasilar Artery Occlusion: A Multicenter, Prospective, Open-Label Randomized Controlled Trial With Blinded Endpoint Assessment
This multicenter, prospective, open-label randomized controlled trial with blinded assessment was designed to assess the efficacy and safety of endovascular treatment for progressive stroke due to vertebrobasilar artery occlusion.
Inclusion: Age ≥18 years; Acute ischemic stroke, with a National Institutes of Health Stroke Scale (NIHSS) score of <10 at initial symptom onset, and no prior endovascular treatment; Stroke progression occurring from 24 hours to 14 days after initial symptom onset, defined as an NIHSS score of ≥10 with an increase of ≥4 points from baseline; Acute basilar artery occlusion or dominant vertebral artery occlusion with contralateral occlusion or hypoplasia, confirmed by CTA, MRA or DSA; Posterior circulation Alberta Stroke Program Early CT Score (pc-ASPECTS) of ≥6 and Pons-Midbrain Index (PMI) of ≤3 on CT or diffusion-weighted imaging (DWI); Randomization within 24 hours of stroke progression; Pre-stroke mRS score of 0-2; Provision of signed informed consent by the patient or their legal representative.
Exclusion: Known pregnancy or lactation, or a positive pregnancy test prior to randomization; Current participation in any other clinical trial of drugs or medical devices, or anticipated participation in another such trial within 3 months after enrollment; Any sign of intracranial hemorrhage (except microbleeds) on baseline brain imaging; Imaging confirms the progression of symptoms caused by intracranial hemorrhage, brain edema, or other clear causes; Refractory hypertension not controlled by medication, defined as systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg; Known dementia or psychiatric disease precluding completion of neurological assessment and follow-up; Life expectancy <1 year, including patients with malignancy or advanced cardiopulmonary disease; Acute ischemic stroke within 48 hours after cardiovascular or cerebrovascular interventional treatment or major surgery; patients presenting >48 hours after such procedures were eligible; Recent (within 1 month) gastrointestinal or genitourinary bleeding, acute myocardial infarction, or traumatic brain injury; Any other condition deemed by the site investigator to make the patient unsuitable for participation; Known hereditary or acquired bleeding diathesis, coagulation factor deficiency, current use of oral anticoagulants with an INR >1.5, or active bleeding; Blood glucose <2.8 or >22.2 mmol/L; platelet count <100 × 10⁹/L; estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m² or serum creatinine ≥177 μmol/L (2.0 mg/dL); Extensive cerebellar infarction with significant mass effect or bilateral thalamic infarction on baseline neuroimaging; Presence of untreated intracranial aneurysm, intracranial tumor (except small meningioma and aneurysms <3 mm in diameter), or intracranial arteriovenous malformation; Known or highly suspected chronic responsible artery occlusion; Presence of severe stenosis in the extracranial or intracranial segment of the responsible artery, arterial dissection, or excessive vascular tortuosity that may prevent successful delivery or navigation of endovascular devices; Known contraindication to contrast medium (except mild rash); Multivessel severe stenosis or occlusion confirmed by CTA, MRA, or DSA; Known or suspected central nervous system vasculitis.